Alpha Pro Tech, Ltd. (APT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 527.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 4.64M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $527.00K | $4.64M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $536.00K | $3.96M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $540.00K | $3.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $544.00K | $3.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $517.00K | $3.20M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $490.00K | $3.58M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $463.00K | $3.45M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $429.00K | $3.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $344.00K | $4.43M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $257.00K | $4.03M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $170.00K | $4.13M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $96.00K | $3.92M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $104.00K | $3.14M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $114.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $147.00K | $4.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $196.00K | $4.74M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $233.00K | $4.94M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $269.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $315.00K | $7.93M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $339.00K | $16.14M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $361.00K | $25.66M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $385.00K | $31.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-30 | (m) | (m) | (m) | $31.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $375.00K | $31.58M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $372.00K | $22.93M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $374.00K | $13.47M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $420.00K | $6.29M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $451.00K | $3.02M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $473.00K | $3.18M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $496.00K | $4.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $476.00K | $4.45M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $432.00K | $3.87M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $364.00K | $3.43M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $329.00K | $2.78M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $293.00K | $2.69M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | (m) | $296.00K | $2.93M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $319.00K | $3.54M | (m) | (m) | (m) | (m) | (m) |
| 2017-07-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $319.00K | $3.63M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $255.00K | $3.70M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $190.00K | $3.67M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $121.00K | $3.36M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $47.00K | $2.88M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $34.00K | $2.03M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $24.00K | $1.48M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $26.00K | $1.77M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $28.00K | $2.46M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $31.00K | $3.24M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $33.00K | $3.22M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $34.00K | $3.00M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $58.00K | $2.81M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $103.00K | $2.48M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $150.00K | $2.40M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $198.00K | $1.76M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $222.00K | $1.11M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $226.00K | $828.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $228.00K | $817.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $221.00K | $1.33M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $236.00K | $1.27M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $250.00K | $1.22M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $268.00K | $905.00K | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $193.00K | $1.74M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| Lifeward Ltd. (LFWD) | $0.021B | ||
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| ENvue Medical, Inc. (FEED) | United States | $0.011B | |
| Bone Biologics Corp (BBLG) | United States | $0.001B | |
| LogicMark, Inc. (LGMK) | United States | $0.000B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| NutriBand Inc. (NTRB) | United States | $0.109B |